Skip to main content
. 2022 Dec;10(24):1374. doi: 10.21037/atm-22-6089

Figure 9.

Figure 9

Correlation analysis between RRM2 expression and clinical LC. (A) Correlation analysis between RRM2 expression and T stage. The P values for stage T1 and stages T2, T3, and T4 were 4.2e−05, 0.24, and 0.52, respectively. (B) Correlation analysis of RRM2 expression and N staging: the P values for N0 and N1, N2, and N3 were 0.00085, 0.002, and 0.94, respectively. (C) Correlation analysis between RRM2 expression and M staging: the P value for M0 and M1 was 0.069. (D) Correlation analysis of RRM2 expression and staging: the P values for stage I and stages II, III, and IV were 0.0021, 0.005, and 0.031, respectively. (E) Analysis of RRM2 expression and age (>65- and ≤65-year groups). The expression of RRM2 in the ≤65-year group was higher than that in the >65-year group, P<0.05. (F) Analysis of RRM2 expression and sex. The RRM2 expression level in males was higher than that in females, with a P value of 0.095. (G) Forest plot of the univariate Cox regression analysis of risk score and clinical characteristics. A significant P value indicates a relationship between characteristics and clinical prognosis. A hazard ratio greater than 1 indicates high-risk factors, and that less than 1 indicates low-risk factors; the 95% CI is in parentheses. (H) Forest plot of multivariate Cox regression analysis of risk score and clinical characteristics. A significant P value indicates a relationship between characteristics and clinical prognosis. A hazard ratio greater than 1 represents high-risk factors, and that less than 1 represents low-risk factors. CI, confidence interval; RRM2, ribonucleotide reductase regulatory subunit M2.